James Sapirstein, CEO of AzurRx BioPharma, Inc. talks about their biopharmaceutical products.

Click the Subscribe button for the latest in crypto, blockchain and business news from NEW TO THE STREET!

See the full episode at: https://newtothestreet.com/new-to-the-street-june-6th-digital-development-partners-azurrx-biopharma-tgi-solar-power-group-tamino-minerals-askvet-globex

#crypto #cryptocurrency #blockquake #blockchain #blockchainnews #digitalcurrency #newtothestreet #janeking #exploringtheblock #foxbusinessnews #foxbusiness #financialnews #businessnews #ai #newsmaxtv #AzurRx

The show interviews James Sapirstein, Chairman & CEO of AzurRx BioPharma, Inc. (NASDAQ: AZRX), talking about AZRX’s biopharmaceutical products and therapies. He gives a comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, provides insight on its FDA Phase 2 clinical trials on its lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/channel/UCceRKKS0QUfXlKUPBoxdTHQ

Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
About New to the Street: https://newtothestreet.com/

Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list